IBB241108P136000
- 0.25
- -0.25-50.00%
iShares Biotechnology ETF Newsroom
Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What's Driving Markets Tuesday?
We Want YOU to Submit Questions for Election Night
10 Health Care Stocks Whale Activity In Today's Session
Peering Into IQVIA Hldgs's Recent Short Interest
RBC Capital Reiterates Outperform on IQVIA Hldgs, Maintains $270 Price Target
Market Climbs for Election Day Excitement | Live Stock
Vertex Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Issued FY24 Product Revenue Guidance Above Estimates. Also, Morgan Stanley Maintained an Equal-Weight Rating on the Stock and...
Arcellx Issues Updates on Anito-cel Clinical Trials
Gilead's Kite To Highlight CAR T-Cell Therapy Portfolio At ASH 2024, Including Survival Outcomes In Both Clinical Trials And The Real-World
This EBay Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Assessing Vertex Pharmaceuticals: Insights From 11 Financial Analysts
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday as US Heads to Polls for 2024 Presidential Elections
Vertex Pharmaceuticals Analyst Ratings
Vertex Pharmaceuticals Incorporated (VRTX) Q3 2024 Earnings Call Transcript Summary
Monday Market Moves Sideways, Election and FOMC in Sight | Wall Street Today
Vertex Raises 2024 Product Revenue Outlook Following Q3 Beats
Vertex Pharmaceuticals Non-GAAP EPS of $4.38 Beats by $0.25, Revenue of $2.77B Beats by $80M
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Editas Downgraded to Market Perform by Raymond James
BioNTech SE (BNTX) Q3 2024 Earnings Call Transcript Summary